Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 28

Results For "lung"

406 News Found

SPARSH Hospitals, MGM Healthcare, Chennai to offer heart failure management program in Bengaluru
Healthcare | October 03, 2022

SPARSH Hospitals, MGM Healthcare, Chennai to offer heart failure management program in Bengaluru

This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant


Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension
Drug Approval | October 01, 2022

Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension

Sildenafil for Oral Suspension had annual sales of USD 65 million in the United States according to IQVIA data (IQVIA MAT Aug 2022).


Cardiac Surgeons call for lifestyle and dietary changes on World Heart Day
Healthcare | September 28, 2022

Cardiac Surgeons call for lifestyle and dietary changes on World Heart Day

There are certain foods can influence blood pressure, triglycerides, cholesterol levels and inflammation, all of which are risk factors for heart disease.


Aptar Pharma collaborates with Fluidda
News | September 25, 2022

Aptar Pharma collaborates with Fluidda

The companies will leverage their respective proprietary technology platforms


Fujifilm India launches campaign to promote early diagnosis of TB
Healthcare | September 20, 2022

Fujifilm India launches campaign to promote early diagnosis of TB

The campaign will also focus on providing doorstep TB screening services to facilitate diagnosis


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Clinical Trials | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials


Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints
Clinical Trials | September 06, 2022

Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease


Merck to present new data of oncology portfolio at ESMO 2022
Clinical Trials | August 30, 2022

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)


Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles
News | August 27, 2022

Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles

The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive


Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Drug Approval | August 27, 2022

Lupin receives UK MHRA Approval of Lutio for treatment of COPD

Lutio has the potential to offer significant cost savings when available to UK patients.